Bertrand Leblond
63-65 Boulevard Masséna
Paris, 75013, France
Paris, 75013, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Synthesis, biological evaluation, and stability studies of raloxifene mono- and bis-sulfamates as dual-targeting agents.
Journal: Bioorganic & medicinal chemistry
Published: January 10, 2024
An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases.
Journal: Journal of medicinal chemistry
Published: October 22, 2016
Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.
Journal: Oncotarget
Published: August 26, 2016
DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3.
Journal: The Journal of experimental medicine
Published: January 02, 2015
A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Journal: Journal of neurochemistry
Published: August 22, 2014
Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part II.
Journal: Molecules (Basel, Switzerland)
Published: August 07, 2014
Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part I.
Journal: Molecules (Basel, Switzerland)
Published: July 29, 2014
Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor.
Journal: Investigational new drugs
Published: May 14, 2012
Synthesis and evaluation of analogues of estrone-3-O-sulfamate as potent steroid sulfatase inhibitors.
Journal: Bioorganic & medicinal chemistry
Published: January 09, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026